Stage III NSCLC RWE in Chinese Patients

Trial Identifier: D4194R00009
Sponsor: AstraZeneca
NCTID:: NCT04023812
Start Date: July 2019
Primary Completion Date: July 2024
Study Completion Date: July 2024
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China BeiJing, China, 100020
China BeiJing, China, 100044
China BeiJing, China
China ChangChun, China, 130021
China ChengDu, China, 610041
China ChengDu, China, 610042
China DaTong, China, 030000
China DaTong, China
China FenYang, China
China GuangZhou, China
China HeFei, China, 330006
China HongKong, China
China JiNan, China, 2501117
China NanNing, China, 530021
China QingDao, China
China ShangHai, China, 200030
China ShangHai, China, 200040
China ShangHai, China
China ShanTou, China
China ShiJiaZhuang, China, 063000
China ShiJiaZhuang, China, 430079
China ShiJiaZhuang, China, 050011
China TaiZhou, China
China TianJin, China
China YinChuan, China, 750004